Back HIV/AIDS GRACE Trial Finds Women Respond as Well as Men to HIV Treatment, but More Likely to Stop Therapy


GRACE Trial Finds Women Respond as Well as Men to HIV Treatment, but More Likely to Stop Therapy

Below is an excerpt from a press release issued by Tibotec, which produces darunavir, describing the GRACE study and its findings.

Data from Landmark Study Evaluating Gender Differences in Response to an HIV Therapy Published in Annals of Internal Medicine

The GRACE study has significant implications for inclusion of women in clinical trials

Titusville, NJ -- September 20, 2010 -- Data from the GRACE (Gender, Race And Clinical Experience) study will be published in the September 21st issue of the Annals of Internal Medicine. GRACE is the largest-ever study of treatment-experienced adult women with HIV-1 to examine gender differences in response to HIV therapy. Sponsored by Tibotec Therapeutics Clinical Affairs, a division of Centocor Ortho Biotech Services, LLC, the GRACE study enrolled 67 percent women, demonstrating that it is possible to recruit large numbers of women into U.S.-based HIV treatment studies. The company has launched to share learnings from the GRACE study and other information for women living with HIV.

Among patients who completed the study, there were no significant differences in treatment responses between men and women who were given Prezista (darunavir) 600 mg coadministered with 100 mg ritonavir twice daily, as part of combination therapy. The GRACE study was designed in partnership with the HIV community and used unique strategies to encourage women living with HIV to participate in the trial. However, even with its novel enrollment strategies, the study showed a higher discontinuation rate among female study participants -- making the overall response rate lower among women than among men, and shedding light on the need for additional efforts to retain diverse populations in clinical studies.

"Better representation of women in clinical trials is essential for generating accurate information on the efficacy and safety of medicines and, ultimately, guiding treatment decisions," said Judith Currier, MD, Professor of Medicine, Associate Division Chief, Division of Infectious Diseases, University of California, Los Angeles, Director of the Clinical Trials Unit, UCLA Center for Clinical AIDS Research and Education (CARE), and primary investigator in the GRACE study. "The GRACE study has the potential to shape how future studies are conducted because it addressed the social and economic barriers that historically have prevented women from participating in clinical research. It also showed that we have a long way to go before we can fully overcome these barriers."

In the United States, women account for an increasing proportion of people living with HIV/AIDS, including more than one quarter of new diagnoses. Yet despite their growing numbers, women have been under-represented in HIV treatment studies. This may be due to recruitment and retention challenges including family commitments, time constraints with jobs, and other socioeconomic factors. These observations have been noted in clinical trials of other therapeutic areas, including heart disease and cancer, suggesting that difficulties in recruiting women are not specific to HIV clinical trials. As a result of having a low number of women in these studies, gender-based conclusions are limited, and there remains a gap in clinical data.

"Unlike most studies of HIV medicines, GRACE was specifically designed and powered to assess gender differences in response to treatment," said Dr. Currier. "We took steps that have never before been used to make sure our study population was reflective of the demographics of women with HIV in the United States."

GRACE Study Design and Results

GRACE was a multi-center (65 sites), open-label Phase 3b trial that compared the efficacy, safety, and tolerability of the protease inhibitor Prezista (600 mg) boosted with a low dose of ritonavir (100 mg) twice a day, in combination with an investigator-selected optimized background regimen for 48 weeks in men (n=142) and women (n=287).

The study was designed to enroll a high proportion of North American, treatment-experienced women that was reflective of the distribution and demographics of women with HIV in the United States. Trial sites were selected to correspond with the geographic distribution of women with HIV, with the majority of sites located in the Northeastern (16 sites) and Southeastern (29 sites) United States. Study sites were initially required to enroll three women before enrolling a man, and thereafter, each site was required to maintain at least 70 percent female enrollment. Men could only be enrolled if their addition did not compromise the 70 percent female quota.

GRACE participants also received support to cover costs associated with study participation, including assistance for travel, childcare and food vouchers, and study sites could access grants for patient support activities such as lunch-and-learn sessions and patient support groups for ongoing education and camaraderie.

At the end of the study period, there were no statistically significant differences in virologic response (defined as a viral load of < 50 copies/mL) rates between women and men. Results from an intent-to-treat time-to-loss of virological response analysis (ITT-TLOVR) showed that 50.9 percent of women reached an undetectable viral load (< 50 copies/mL) at week 48 compared with 58.5 percent of men (p=not significant). These figures included men and women who had discontinued the study. When treatment discontinuations for reasons other than virologic failure were discounted, 73 percent of women and 73.5 percent of men reached an undetectable viral load (p=not significant).

Discontinuation rates driven by reasons other than virologic failure were 32.8 percent for women versus 23.2 percent for men. Loss to follow-up was the most common reason for discontinuation. There were no clinically relevant differences in safety or tolerability between women and men. In adult patients receiving a Prezista/ritonavir-containing regimen, the most common treatment-related adverse events (? 2 percent) reported of at least moderate to severe intensity (> Grade 2) were nausea (5.2 percent for women and 2.8 percent for men), diarrhea (4.5 percent for women and 4.9 percent for men) and rash (2.1 percent for women and 2.8 percent for men).

Additional analyses were conducted as part of the GRACE study, including a sub-study examining efficacy and safety differences in response to race, as well as an immunology sub-study.

Full prescribing information for darunavir is available at

About Tibotec Therapeutics

Tibotec Therapeutics, a division of Centocor Ortho Biotech Products, LP, headquartered in Titusville, NJ, is dedicated to delivering innovative virology therapeutics that help healthcare professionals address serious unmet needs in people living with HIV. For more information, visit

Investigator affiliations: University of California, Los Angeles, School of Medicine, Los Angeles, CA; The Well Project, Nellysford, VA; Chatham County Health Department, Savannah, GA; University of Puerto Rico School of Medicine, San Juan, PR; University of Cincinnati College of Medicine, Cincinnati, OH; Tibotec and Tibotec Therapeutics, Titusville, NJ: Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA.



J Currier, D Averitt Bridge, D Hagins, and others (GRACE Study Group). Sex-Based Outcomes of Darunavir-Ritonavir Therapy: A Single-Group Trial. Annals of Internal Medicine 153(6): 349-357 (Abstract). September 21, 2010.

Other Source

Tibotec. Data from Landmark Study Evaluating Gender Differences in Response to an HIV Therapy Published in Annals of Internal Medicine. Press release. September 20, 2010.